<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114619</url>
  </required_header>
  <id_info>
    <org_study_id>920800</org_study_id>
    <nct_id>NCT02114619</nct_id>
  </id_info>
  <brief_title>Comparative Study of Different I-131 Doses in Graves' Disease</brief_title>
  <official_title>The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radioactive iodine (RAI) administration is an effective and completely established treatment
      modality in hyperthyroidism including Graves' disease. Despite the long experience with
      radioiodine for hyperthyroidism, controversy remains regarding the optimal dose of iodine
      that is required to achieve long-term euthyroidism. The fixed activity administration method
      does not optimize the therapy, giving often too high or too low radiation to the gland, but
      the optimal dose per gram of thyroid mass in calculated activity administration method is
      also under much debates. This prospective study has been designed in order to compare the
      effect of different calculated doses of radioiodine on Graves' disease treatment outcome.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of thyroid related hormones blood level from baseline at 1,3,6 and 12 month</measure>
    <time_frame>1,3,6,12 month</time_frame>
    <description>thyroid-stimulating hormone (TSH), T4, T3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of hypothyroidism status at 1, 3,6 and 12 month post RAI therapy</measure>
    <time_frame>1,3,6,12 month</time_frame>
    <description>Hypothyroidism index</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of thyroid volume</measure>
    <time_frame>1,3,6 and 12 months</time_frame>
    <description>Change of thyroid volume 1,3,6 and 12 months after therapy using ultrasonography</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Graves' Disease</condition>
  <arm_group>
    <arm_group_label>Low dose of I-131</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Graves' disease who will be treated with I-131, using 100 microcurie per gram (uCi/gr) of thyroid weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Graves' disease who will be treated with 150 microcurie (uCi) of I-131 per gram of thyroid weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Graves' disease who will be treated with I-131 using 200 uCi/gr of thyroid weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose of I-131</intervention_name>
    <description>We wil administer 100 micro currie of iodine per thyroid gram</description>
    <arm_group_label>Low dose of I-131</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intermediate dose</intervention_name>
    <description>We will administer 150 micro currie of iodine per thyroid gram</description>
    <arm_group_label>Intermediate dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose</intervention_name>
    <description>We will administer 200 micro currie of iodine per thyroid gram</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 hyperthyroid patients (Graves'disease)

        Exclusion Criteria:

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narjess Ayati, MD, FEBNM</last_name>
    <role>Study Director</role>
    <affiliation>Nuclear Medicine Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seyed Rasoul Zakavi, MD. IBNM</last_name>
    <phone>+98-511 8012799</phone>
    <email>Zakavir@mums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Narjess Ayati, MD. FEBNM</last_name>
    <phone>+98-511 8012782</phone>
    <email>Ayatin@mums.ac.ir</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nuclear Medicine Research Center, Ghaem Hospital</name>
      <address>
        <city>Mashhad</city>
        <state>Khorasan-Razavi</state>
        <zip>9919991766</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zohre Mousavi, MD. IBE</last_name>
      <phone>+98-5118599359</phone>
      <email>Mosaviz@mums.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Ramin Sadeghi, MD. IBNM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seyed Rasoul Zakavi, MD. IBNM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>S.R.ZAKAVI</investigator_full_name>
    <investigator_title>Head of Nuclear Medicine Research Center</investigator_title>
  </responsible_party>
  <keyword>radioiodine therapy</keyword>
  <keyword>Graves' disease</keyword>
  <keyword>Hyperthyroidism</keyword>
  <keyword>calculated dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

